Arkolith/Insider Trading/LYEL/Form 4

Seely Lynn

President and CEO, DirectorLyell Immunopharma, Inc. (LYEL) · full profile →Form 4 · filed Aug 22, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$76K
Net Open-Market Flow
-$76K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 21, 2025Sell(S)7K$10.54$76K68K
Aug 20, 2025Grant(A)40K—$075K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-022747) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML